Jean‐François Baladi

1.5k total citations
29 papers, 1.1k citations indexed

About

Jean‐François Baladi is a scholar working on Genetics, Hematology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Jean‐François Baladi has authored 29 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Genetics, 13 papers in Hematology and 9 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Jean‐François Baladi's work include Hemoglobinopathies and Related Disorders (17 papers), Iron Metabolism and Disorders (11 papers) and Pharmacological Effects and Toxicity Studies (9 papers). Jean‐François Baladi is often cited by papers focused on Hemoglobinopathies and Related Disorders (17 papers), Iron Metabolism and Disorders (11 papers) and Pharmacological Effects and Toxicity Studies (9 papers). Jean‐François Baladi collaborates with scholars based in United States, Switzerland and France. Jean‐François Baladi's co-authors include Simu K. Thomas, Thomas D. Coates, Thomas E. Delea, Pradyumna D. Phatak, Diana Rofail, Linda Abetz, Oleg Sofrygin, Alan K. Hatfield, Jörge E. Cortes and Devidas Menon and has published in prestigious journals such as Blood, Transplantation and The Oncologist.

In The Last Decade

Jean‐François Baladi

29 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jean‐François Baladi United States 18 629 593 241 166 126 29 1.1k
Irene Agodoa United States 18 418 0.7× 426 0.7× 175 0.7× 71 0.4× 37 0.3× 48 1.1k
Biswajit Dubashi India 15 179 0.3× 210 0.4× 135 0.6× 23 0.1× 115 0.9× 131 883
Palle Bager Denmark 19 150 0.2× 330 0.6× 57 0.2× 57 0.3× 97 0.8× 46 1.2k
Dennis J. Cotter United States 14 166 0.3× 492 0.8× 32 0.1× 150 0.9× 44 0.3× 24 1.0k
Hannah Bower Sweden 16 478 0.8× 656 1.1× 48 0.2× 95 0.6× 81 0.6× 42 1.3k
Menaka Bhor United States 14 325 0.5× 333 0.6× 136 0.6× 30 0.2× 97 0.8× 52 623
George J Joseph United States 15 92 0.1× 147 0.2× 41 0.2× 104 0.6× 16 0.1× 25 537
AH Partridge United States 6 69 0.1× 62 0.1× 186 0.8× 73 0.4× 103 0.8× 30 754
Anna Christofides Canada 17 204 0.3× 389 0.7× 59 0.2× 15 0.1× 89 0.7× 41 927
Bart Heeg United States 19 53 0.1× 370 0.6× 56 0.2× 342 2.1× 65 0.5× 102 1.1k

Countries citing papers authored by Jean‐François Baladi

Since Specialization
Citations

This map shows the geographic impact of Jean‐François Baladi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean‐François Baladi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean‐François Baladi more than expected).

Fields of papers citing papers by Jean‐François Baladi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean‐François Baladi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean‐François Baladi. The network helps show where Jean‐François Baladi may publish in the future.

Co-authorship network of co-authors of Jean‐François Baladi

This figure shows the co-authorship network connecting the top 25 collaborators of Jean‐François Baladi. A scholar is included among the top collaborators of Jean‐François Baladi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean‐François Baladi. Jean‐François Baladi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Casciano, Roman, Giuseppe Di Lorenzo, Zhimei Liu, et al.. (2011). Economic Evaluation of Everolimus versus Sorafenib for the Treatment of Metastatic Renal Cell Carcinoma after Failure of First-Line Sunitinib. Value in Health. 14(6). 846–851. 28 indexed citations
2.
Lebwohl, David, George Thomas, Heidi A. Lane, et al.. (2011). Research and innovation in the development of everolimus for oncology. Expert Opinion on Drug Discovery. 6(3). 323–338. 25 indexed citations
3.
Rofail, Diana, Muriel Viala, Adam Gater, et al.. (2010). An instrument assessing satisfaction with iron chelation therapy: Psychometric testing from an open-label clinical trial. Advances in Therapy. 27(8). 533–546. 11 indexed citations
4.
Vichinsky, Elliott, Zahra Pakbaz, Onyinye Onyekwere, et al.. (2008). Patient-Reported Outcomes of Deferasirox (Exjade®, ICL670) versus Deferoxamine in Sickle Cell Disease Patients with Transfusional Hemosiderosis. Acta Haematologica. 119(3). 133–141. 55 indexed citations
5.
6.
Payne, Krista, Diana Rofail, Jean‐François Baladi, et al.. (2008). Iron chelation therapy: Clinical effectiveness, economic burden and quality of life in patients with iron overload. Advances in Therapy. 25(8). 725–742. 60 indexed citations
7.
Darkow, Theodore, Henry J. Henk, Simu K. Thomas, et al.. (2007). Treatment Interruptions and Non-Adherence with Imatinib and Associated Healthcare Costs. PharmacoEconomics. 25(6). 481–496. 233 indexed citations
8.
Delea, Thomas E., Oleg Sofrygin, Simu K. Thomas, et al.. (2007). Cost Effectiveness of Once-Daily Oral Chelation Therapy with Deferasirox versus Infusional Deferoxamine in Transfusion-Dependent Thalassaemia Patients. PharmacoEconomics. 25(4). 329–342. 70 indexed citations
9.
Payne, Krista, Marie‐Pierre Desrosiers, J. Jaime, et al.. (2007). Clinical and economic burden of infused iron chelation therapy in the United States. Transfusion. 47(10). 1820–1829. 36 indexed citations
10.
Delea, Thomas E., May Hagiwara, Simu K. Thomas, et al.. (2007). Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States. American Journal of Hematology. 83(4). 263–270. 28 indexed citations
11.
Delea, Thomas E., John Edelsberg, Oleg Sofrygin, et al.. (2007). Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion‐dependent thalassemia: a literature review. Transfusion. 47(10). 1919–1929. 147 indexed citations
12.
Abetz, Linda, et al.. (2006). The impact of iron overload and its treatment on quality of life: results from a literature review. Health and Quality of Life Outcomes. 4(1). 73–73. 88 indexed citations
13.
Delea, Thomas E., Oleg Sofrygin, Simu K. Thomas, et al.. (2005). Cost-Effectiveness of Once-Daily Oral Chelation Therapy with Deferasirox (Exjade®, ICL670) Versus Infusional Deferoxamine in Transfusion-Dependent Thalassemic Patients.. Blood. 106(11). 1341–1341. 2 indexed citations
14.
Keown, Paul, Robert Balshaw, Hans Krueger, & Jean‐François Baladi. (2001). ECONOMIC ANALYSIS OF BASILIXIMAB IN RENAL TRANSPLANTATION1. Transplantation. 71(11). 1573–1579. 55 indexed citations
15.
Baladi, Jean‐François, Peter Bailey, Sandra E. Black, et al.. (2000). Rivastigmine for alzheimer's disease: Canadian interpretation of intermediate outcome measures and cost implications. Clinical Therapeutics. 22(12). 1549–1561. 11 indexed citations
16.
Baladi, Jean‐François, et al.. (1998). Use of economic evaluation guidelines: 2 years’ experience in Canada. Health Economics. 7(3). 221–227. 36 indexed citations
17.
Baladi, Jean‐François, et al.. (1998). Use of economic evaluation guidelines: 2 years’ experience in Canada. Health Economics. 7(3). 221–227. 4 indexed citations
18.
Jacobs, Philip & Jean‐François Baladi. (1996). Biases in cost measurement for economic evaluation studies in health care. Health Economics. 5(6). 525–529. 24 indexed citations
19.
Baladi, Jean‐François, et al.. (1996). An Economic Evaluation of Finasteride for Treatment of Benign Prostatic Hyperplasia. PharmacoEconomics. 9(5). 443–454. 46 indexed citations
20.
Jacobs, Philip, et al.. (1995). A Comparative Review of Pharmacoeconomic Guidelines. PharmacoEconomics. 8(3). 182–189. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Irene Agodoa Breakdown of academic impact, for papers by Biswajit Dubashi Breakdown of academic impact, for papers by Palle Bager Breakdown of academic impact, for papers by Dennis J. Cotter Breakdown of academic impact, for papers by Hannah Bower Breakdown of academic impact, for papers by Menaka Bhor Breakdown of academic impact, for papers by George J Joseph Breakdown of academic impact, for papers by AH Partridge Breakdown of academic impact, for papers by Anna Christofides Breakdown of academic impact, for papers by Bart Heeg
Rankless by CCL
2026